Generics Cos. Can't Pare Novartis Patent Infringement Suit

Law360, New York (October 23, 2013, 8:03 PM ET) -- A New Jersey federal judge on Wednesday denied a bid by Apotex Inc. and other generic-drug makers to trim Novartis Pharmaceuticals Corp.'s suit against them, saying it was too early in the proceeding to determine whether their use of a drug ingredient infringed Novartis' patents.

Novartis has targeted more than a dozen generic-drug makers, including Apotex, Sun Pharmaceutical Industries Ltd. and Wockhardt USA LLC, seeking to block the companies from producing zoledronic acid, the active ingredient in its osteoporosis drug Reclast and oncology drug Zometa. Novartis...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required